Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12480947 | 0.80 | ACHE (0.48) | ACHERAB9AHTR1ALMNAPOLB | |
| SCHEMBL12479840 | 0.80 | ACHE (0.50) | ACHERAB9AHTR1APOLB | |
| SCHEMBL10119653 | 0.75 | RAB9A (0.47) | ACHERAB9AHTR1ALMNAPOLB | |
| SCHEMBL12479755 | 0.74 | MTNR1A (0.73) | — | |
| SCHEMBL12483925 | 0.73 | KDM4E (0.42) | LMNAGAA | |
| SCHEMBL6787435 | 0.70 | KDM4E (0.49) | ACHELMNAALDH1A1GAA | |
| SCHEMBL6301799 | 0.70 | CYP19A1 (0.53) | LMNAGAA | |
| SCHEMBL5480835 | 0.70 | CYP24A1 (0.46) | LMNAGAA | |
| SCHEMBL7554454 | 0.70 | MEN1 (0.47) | RAB9AHTR1ALMNAALDH1A1MEN1 | |
| SCHEMBL10467454 | 0.69 | KDM4E (0.48) | ACHELMNAALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661423-B1 | NEW PROCESSS FOR THE SYNTHESIS OF AGOMELATINE | SERVIER LAB (FR) | 2015-03-11 | — | — | EP | claimed |
| US-8871975-B2 | Process for the synthesis of agomelatine | LES LABORATORIES SERVIER (FR) | 2014-10-28 | — | — | US | claimed |
| US-20130289308-A1 | PROCESS FOR THE SYNTHESIS OF AGOMELATINE | LES LABORATOIRES SERVIER (FR) | 2013-10-31 | — | — | US | claimed |
| EP-2661423-B1 | NEW PROCESSS FOR THE SYNTHESIS OF AGOMELATINE | SERVIER LAB (FR) | 2015-03-11 | — | — | EP | disclosed |
| US-8871975-B2 | Process for the synthesis of agomelatine | LES LABORATORIES SERVIER (FR) | 2014-10-28 | — | — | US | disclosed |
| EP-2661423-A1 | NOVEL PROCESS FOR SYNTHESIZING AGOMELATINE | Les Laboratoires Servier (FR) | 2013-11-13 | — | — | EP | disclosed |
| US-20130289308-A1 | PROCESS FOR THE SYNTHESIS OF AGOMELATINE | LES LABORATOIRES SERVIER (FR) | 2013-10-31 | — | — | US | disclosed |
| WO-2012093225-A1 | NOVEL PROCESS FOR SYNTHESIZING AGOMELATINE | LES LABORATOIRES SERVIER (FR) | 2012-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289308-A1 | PROCESS FOR THE SYNTHESIS OF AGOMELATINE | COMT, PNMT, TPH1 | ACHE 2215/4885RAB9A 436/4885HTR1A 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.